• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

by MM360 Staff | Jul 3, 2025 | Uncategorized

Source: CureToday articles The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program. Read More

FDA accelerates linvoseltamab-gcpt approval for multiple myeloma

by Lucas Laboy | Jul 2, 2025 | Uncategorized

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome...

Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by MM360 Staff | Jul 2, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Spatial and single cell mapping of castleman disease reveals key stromal cell types and cytokine pathways

by MM360 Staff | Jul 1, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More
« Older Entries
Next Entries »

Recent Content

  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT